Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan

Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan

Purpose: To investigate the clinical predictive factors for the efficacy of everolimus (EVE) for advanced/metastatic breast cancer (AMBC). Methods: Routine practice data of consecutive patients with AMBC who received EVE at 5 institutions in western Japan were retrospectively analyzed in this cohort...

Full description

Bibliographic Details
Main Authors:	Yuichiro Kikawa, Takeshi Kotake, Yukiko Kajiwara, Kazuki Hashimoto, Hiroyasu Yamashiro, Shoichiro Ohtani, Shintaro Takao, Masakazu Toi
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-01-01
Series:	Breast Cancer: Basic and Clinical Research
Online Access:	https://doi.org/10.1177/1178223418825135

Similar Items

Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan—The KBCOG-14 Study
by: Nina Odan, et al.
Published: (2020-12-01)

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
by: Masakazu Toi, et al.
Published: (2017-04-01)

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
by: Hiroyasu Yamashiro, et al.
Published: (2018-07-01)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
by: Mariya Rozenblit, et al.
Published: (2021-01-01)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
by: Li, M., et al.
Published: (2022)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
by: Alexander Chehrazi-Raffle, et al.
Published: (2020-06-01)

Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
by: Berna Öksüzoğlu, et al.
Published: (2020-06-01)

Pathway to psychiatric care in Japan: A multicenter observational study
by: Kikuchi Toshiaki, et al.
Published: (2008-09-01)

Everolimus in kidney transplantation
by: Cooper JE, et al.
Published: (2011-07-01)

Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan
by: Takashi Ono, et al.
Published: (2019-07-01)

Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204
by: Yukihiro Toi, et al.
Published: (2021-07-01)

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials
by: Claudia Sommerer, et al.
Published: (2018-09-01)

Everolimus in Erdheim-Chester disease
by: Mohamed A. Hussein, et al.
Published: (2013-01-01)

The role of everolimus in liver transplantation
by: Ganschow R, et al.
Published: (2014-09-01)

Everolimus in Heart Transplantation: An Update
by: Stephan W. Hirt, et al.
Published: (2013-01-01)

Everolimus-eluting coronary stents
by: Alejandro Saez, et al.
Published: (2010-09-01)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
by: Duan F, et al.
Published: (2021-08-01)

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series <sup>†</sup>
by: Armando Orlandi, et al.
Published: (2020-12-01)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+/− Mice Is Superior to Everolimus Alone
by: Jian Yang, et al.
Published: (2017-02-01)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
by: Eriko Tokunaga, et al.
Published: (2021-08-01)

Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
by: Katsuhiko Nakatsukasa, et al.
Published: (2021-01-01)

Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).
by: Susanne Brakemeier, et al.
Published: (2019-01-01)

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
by: Yuka Shibata, et al.
Published: (2019-07-01)

Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
by: Ryota Kakizaki, et al.
Published: (2020-10-01)

Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
by: Tadahiro Yanagi, et al.
Published: (2019-10-01)

EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01)

Everolimus in the management of metastatic neuroendocrine tumours
by: David L. Chan, et al.
Published: (2017-01-01)

The Role of Everolimus in Renal Cell Carcinoma
by: Malek Meskawi, et al.
Published: (2015-12-01)

Everolimus in the Treatment of Metastatic Breast Cancer
by: Melanie E. Royce, et al.
Published: (2015-01-01)

Everolimus in the Treatment of Metastatic Breast Cancer
by: Melanie E. Royce, et al.
Published: (2015-09-01)

Cellular effects of everolimus and sirolimus on podocytes.
by: Sandra Müller-Krebs, et al.
Published: (2013-01-01)

Interstitial pneumonitis caused by everolimus treatment
by: Nilufer Aykac Kongar, et al.
Published: (2016-03-01)

The use of everolimus in renal-transplant patients
by: Julio Pascual
Published: (2009-06-01)

EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01)

Radiation-Induced Esophagitis Exacerbated by Everolimus
by: Yuji Miura, et al.
Published: (2013-06-01)

Everolimus-eluting stents in interventional cardiology
by: Townsend JC, et al.
Published: (2012-06-01)

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
by: Peter Schmid, et al.
Published: (2021-01-01)

Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
by: Sun B, et al.
Published: (2016-07-01)

Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM
by: M. I. Volkova, et al.
Published: (2019-10-01)

Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T⃰
by: I. Tsimafeyeu, et al.
Published: (2015-06-01)